Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several core labeled items (GLP-1 agonist, once-weekly subcutaneous administration, diabetes efficacy, gastric emptying delay, nausea/vomiting, insulin/sulfonylurea hypoglycemia risk, HbA1c reduction, and cardiovascular/CKD outcomes) are supported by the provided label excerpts. However, multiple additional claims about appetite/food cravings, CCK/PYY, brain receptor activation, and specific neuropsychiatric effects are not supported by the supplied label sections, and several causal/marketing-style statements are unsupported. Safety-critical label elements (contraindications/boxed warnings/specific population guidance) are not evaluated.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist.
11 DESCRIPTION; 12.1 Mechanism of Action
Ozempic is administered via injection once a week.
11 DESCRIPTION (subcutaneous injection); 14.1/14.2/14.3 clinical study descriptions (once weekly dosing)
Ozempic has been shown to be effective in managing type 2 diabetes.
1 INDICATIONS AND USAGE; 14.1 Glycemic Control Trials
Ozempic slows down gastric emptying.
12.1 Mechanism of Action (minor delay in gastric emptying)
Some users have reported experiencing nausea after taking Ozempic.
6.1 Clinical Trials Experience (Table 1: Nausea)
Some users have reported experiencing vomiting after taking Ozempic.
6.1 Clinical Trials Experience (Table 1: Vomiting)
Ozempic can interact with other medications, such as sulfonylureas and insulin.
7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin; 5.5
Ozempic interacting with sulfonylureas and insulin can increase the risk of hypoglycemia.
5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin; 7.1
Ozempic has been shown to reduce HbA1c levels in people with type 2 diabetes.
14.1 Glycemic Control Trials; 1 INDICATIONS AND USAGE
Ozempic can help reduce the risk of complications associated with type 2 diabetes, such as heart disease and kidney disease.
1 INDICATIONS AND USAGE; 14.2 and 14.3
Ozempic can help people with type 2 diabetes manage blood sugar levels more effectively.
1 INDICATIONS AND USAGE; 14.1 Glycemic Control Trials
Unsupported Statements
GLP-1 is released in response to food intake.
Not supported by the provided label excerpts.
One notable side effect of Ozempic is its impact on appetite.
No supplied label excerpt explicitly supports this as a labeled side effect or highlights appetite as a specific adverse reaction.
Many users have reported feeling less hungry while taking Ozempic.
Not supported by the provided label excerpts.
Many users have reported experiencing a reduction in food cravings while taking Ozempic.
Not supported by the provided label excerpts.
Slowing down gastric emptying can lead to feelings of fullness and reduced hunger.
Mechanistic/casual effect statement not supported by the provided label excerpts.
A study in the Journal of Clinical Endocrinology and Metabolism reported that Ozempic activates the GLP-1 receptor in the brain.
No supplied label excerpt supports this journal-specific claim.
Activating the GLP-1 receptor in the brain helps regulate appetite and satiety.
Not supported by the provided label excerpts.
Ozempic stimulates the release of hormones that help regulate hunger and fullness, such as cholecystokinin (CCK) and peptide YY (PYY).
Not supported by the provided label excerpts.
By reducing hunger and increasing feelings of fullness, Ozempic can help people eat fewer calories and lose weight.
Not supported by the provided label excerpts; reads as a causal/behavioral marketing claim beyond what is shown.
Some users have reported feeling anxious while taking Ozempic.
Not supported by the provided label excerpts.
Some users have reported feeling depressed while taking Ozempic.
Not supported by the provided label excerpts.
Ozempic is a brand-name medication.
Not a substantive medical/label claim in the provided label excerpts.
Ozempic is not available in generic form.
Not supported by the provided label excerpts.
A generic version of Ozempic is expected to be approved in the near future.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Contraindications (and related safety criteria such as severe hypersensitivity or other contraindicated conditions) were not evaluated against the provided label excerpts.
Importance:
High
Boxed warning status (if present in the Ozempic label) was not evaluated against the provided label excerpts.
Importance:
High
Specific population labeling (e.g., pregnancy, lactation, pediatric, geriatric) was not evaluated because those sections were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes multiple unsupported mechanistic/appetite/psychiatric claims and causal statements that are not grounded in the provided label excerpts. While some key safety-relevant items present in the excerpts (nausea/vomiting and hypoglycemia risk with sulfonylureas/insulin) are supported, omission of contraindications/boxed warning evaluation prevents a full on-label safety alignment assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the supplied FDA label excerpts (notably appetite/food cravings, CCK/PYY, brain receptor activation, anxiety/depression, and causal calorie-reduction messaging). Safety label elements like contraindications/boxed warnings were not assessed due to missing evaluation scope.
Suggested Improvement
Restrict claims to label-supported information from the provided sections (indications, study-supported outcomes like HbA1c/weight changes, mechanism items explicitly stated such as insulin/glucagon secretion and gastric emptying delay, and adverse reactions/hypoglycemia interaction statements). Remove or rephrase unsupported mechanistic, journal-specific, appetite/food-craving, and neuropsychiatric claims, and ensure contraindications/boxed warning sections are included in the audit/evaluation set.